SecBot SecBot
Biotech Drug Report Generated Nov 2, 2026

VX-993

VRTX·VERTEX PHARMACEUTICALS INC / MA
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
At least several years away, if successful. The DPN Phase 2 data is expected in mid-2027, and Phase 3 trials would follow. No regulatory filings are imminent.
Why 3/10
VX-993 has no upcoming PDUFA or pivotal binary catalyst within the next 12 months; the next catalyst is the Phase 2 DPN topline readout expected in mid-2027, more than 6 months away. Even that readout would affect a small fraction of Vertex's value given its diversified pipeline of approved products (Trikafta, Alyftrek, Casgevy, Journavx) and its pending povetacicept PDUFA in November 2026.
Actionable Insight NEUTRAL

The next catalyst is the Phase 2 DPN topline readout expected in mid-2027; a positive result could revive the program's prospects in chronic pain, while a negative readout would likely end it. For Vertex, this is one of many pipeline programs, but investors should watch upcoming quarterly updates for enrollment-completion confirmation.

Price Chart

Loading chart...

Executive Summary

VX-993 is an oral NaV1.8 sodium channel blocker (pain signal inhibitor) from Vertex Pharmaceuticals, designed as a next-gen follow-up to Vertex's approved Journavx (suzetrigine). In August 2025, the drug failed its Phase 2 acute pain trial, missing the primary endpoint in a bunionectomy study, leading Vertex to discontinue acute pain development. However, a separate Phase 2 trial in diabetic peripheral neuropathy (DPN) is still recruiting. Vertex confirmed in its Q3 2026 earnings release (November 2, 2026) that enrollment in the DPN study remains on track to finish by year-end 2026, with results expected in mid-2027. At a large, diversified biotech like Vertex, VX-993 is a modest pipeline asset with no near-term binary catalyst.

How It Works

VX-993 blocks the NaV1.8 sodium channel on pain-sensing nerve cells in the peripheral nervous system. This channel acts like a relay station: when tissue is injured or damaged, pain signals travel through these channels toward the spinal cord and brain. By blocking the channel, VX-993 aims to prevent pain signals from reaching the brain, without the addictive potential of opioids.

Trial Status

A Phase 2 study in acute pain (bunionectomy) completed and failed to meet its primary endpoint in August 2025. A separate Phase 2 study in diabetic peripheral neuropathy (DPN) NCT06619860 is actively recruiting at 47 sites across 6 countries. Vertex expects enrollment to complete by end of 2026 with topline results in mid-2027.

The Two-Sided Case

▲ Bull Case4
VX-993 addresses a large unmet need: chronic pain affects millions, and non-opioid alternatives are a major market opportunity following Journavx's launch.
Vertex has deep expertise in NaV1.8 biology (Journavx was approved in Jan 2025), and VX-993 could be a complementary or next-gen asset in the same class.
DPN afflicts roughly 20-30% of diabetes patients; even a modest market share in chronic neuropathic pain could generate meaningful revenue for Vertex.
Vertex confirmed in Q3 2026 that enrollment is on track for completion, suggesting the program remains active and adequately resourced.
▼ Bear Case4
The Phase 2 acute pain trial failed to beat placebo, raising questions about VX-993's fundamental efficacy as a NaV1.8 inhibitor versus the already-approved Journavx (suzetrigine).
Vertex already has suzetrigine (Journavx) in Phase 3 for DPN with results due mid-2027; VX-993 may be redundant in Vertex's pain portfolio.
The Phase 2 DPN trial remains in recruiting status as of October 2026, with completion of enrollment pushed to end of 2026 (the initial completion date of May 2026 has passed).
VX-993 is a minor pipeline asset at a ~$137B large-cap biotech, so even positive data would have limited stock impact; failure would be immaterial to Vertex's overall valuation.

Upcoming Catalysts

  • Enrollment completion for Phase 2 DPN study expected by end of 2026
  • Phase 2 DPN topline results expected mid-2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

VERTEX PHARMACEUTICALS INC / MA 8-K VRTX ·Originating report

Sources · 10

Hover a chip for the title
1 investors.vrtx.com2 fiercebiotech.com3 biospace.com4 news.vrtx.com5 marketscreener.com6 businesswire.com7 clinicaltrials.gov8 vrtx.com9 neuropathyresource.com10 medcitynews.com